Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the appointment with immediate effect of Susan Clement-Davies, a highly experienced investment banker, as a Non-Executive Director. Simultaneously, Marc d’Abbadie, a Non-Executive Director and representative of one of the Company’s early stage investors, will step down from the Board.
Susan has more than 25 years of capital markets and investment banking experience gained at banks including Bank of Tokyo (now MUFG Bank), BZW (now Barclays) and Citigroup. She worked as a managing director at Torreya Partners LLC, a global investment bank focused on life sciences, from 2014 until earlier this year. Susan’s charitable work includes positions on the fund-raising committees of the Institute of Cancer Research and Great Ormond Street Hospital.
Barry Clare, Evgen Pharma plc Chairman, said:
“I’m delighted to welcome Susan Clement-Davies to Evgen’s Board. Her extensive investment banking and life sciences experience will be of great value to the Company as we prepare for the commercialisation of our product pipeline. On behalf of the Board, I would like to extend our thanks to Marc d’Abbadie for his support and guidance both before and after Evgen’s AIM flotation. We wish him well for the future.”